Shearman & Sterling has acted opposite Davis Polk & Wardwell on the $4bn acquisition of generic pharmaceutical company Ranbaxy by India's Sun Pharmaceutical Industries.
April 08, 2014 at 03:31 AM
1 minute read
The original version of this story was published on Legalweek
Shearman & Sterling has acted opposite Davis Polk & Wardwell on the $4bn acquisition of generic pharmaceutical company Ranbaxy by India’s Sun Pharmaceutical Industries.
The deal, expected to close in December, will create the fifth-largest specialty generics company in the world and the largest pharmaceutical business in India, with 65 outlets and 47 manufacturing facilities across five continents.
Presented by BigVoodoo
Celebrate outstanding achievement in law firms, chambers, in-house legal departments and alternative business structures.
The African Legal Awards recognise exceptional achievement within Africa s legal community during a period of rapid change.
Law firms & in-house legal departments with a presence in the middle east celebrate outstanding achievement within the profession.
A large and well-established Tampa company is seeking a contracts administrator to support the company's in-house attorney and manage a wide...
We are seeking an attorney to join our commercial finance practice in either our Stamford, Hartford or New Haven offices. Candidates should ...
We are seeking an attorney to join our corporate and transactional practice. Candidates should have a minimum of 8 years of general corporat...
MELICK & PORTER, LLP PROMOTES CONNECTICUT PARTNERS HOLLY ROGERS, STEVEN BANKS, and ALEXANDER AHRENS
